Market Place
Sourcing Support
Robbins LLP Urges RARE Securities Investors to Join Fraud Suit
25 Mar 2026 //
PHARMIWEB
Ultragenyx To Participate At Investor Conferences In March
23 Feb 2026 //
GLOBENEWSWIRE
Robbins LLP Alerts Investors Of Ultragenyx Pharma Pharma Lawsuit
05 Feb 2026 //
PHARMIWEB
Ultragenyx To Host Q4 2025 Financial Results Conference Call
05 Feb 2026 //
GLOBENEWSWIRE
Ultragenyx Plans Cost-Cutting Push After Flunking Phase 3 Trials
02 Jan 2026 //
FIERCE BIOTECH
Ultragenyx To Host Q3 2025 Financial Results Conference Call
28 Oct 2025 //
GLOBENEWSWIRE
Ultragenyx Reports Positive Phase 3 Data on DTX401 Gene Therapy
08 Sep 2025 //
GLOBENEWSWIRE
Ultragenyx Starts BLA Submission for Dtx401 Gene Therapy in GSDIa
18 Aug 2025 //
GLOBENEWSWIRE
FDA Snubs Ultragenyx Gene Therapy Over Manufacturing Issues
11 Jul 2025 //
PRESS RELEASE
Europe Extends Evkeeza Approval To HoFH Children Aged Six Months+
06 Jan 2025 //
GLOBENEWSWIRE
NHS England Rolls Out Evkeeza® for HoFH Patients Aged 12 and Older
20 Dec 2024 //
GLOBENEWSWIRE
Ultragenyx Submits BLA for UX111 Therapy for Sanfilippo Syndrome
19 Dec 2024 //
GLOBENEWSWIRE
Ultragenyx Doses 1st Patient in Ph 3 Study for Angelman Syndrome
19 Dec 2024 //
GLOBENEWSWIRE
Ultragenyx Updates on GTX-102 in Angelman Syndrome at FAST Summit
09 Nov 2024 //
GLOBENEWSWIRE
Ultragenyx tweaks gene therapy dosing to dial up efficacy
04 Oct 2024 //
FIERCE BIOTECH
Ultragenyx Updates On Cyprus2+ Study Of UX701 For Wilson Disease
03 Oct 2024 //
GLOBENEWSWIRE
INKmune Demonstrates Safety And NK-Cell Activity In First Cohort
26 Sep 2024 //
GLOBENEWSWIRE
Ultragenyx eyes accelerated US filing for Sanfilippo gene therapy
14 Jun 2024 //
FIERCE BIOTECH
Ultragenyx Completes Enrollment in Ph3 Setrusumab OI Studies ORBIT, COSMIC
30 Apr 2024 //
GLOBENEWSWIRE
Ultragenyx Announces Data Demonstrating Treatment with UX111 Results
06 Feb 2024 //
GLOBENEWSWIRE
Ultragenyx Receives PRIME Designation from EMA for GTX-102
05 Feb 2024 //
GLOBENEWSWIRE
Ultragenyx nears $50M Series A for its Alzheimer`s gene therapy spinout: #JPM24
09 Jan 2024 //
ENDPTS
Ultragenyx Announces Completion of Enrollment in Phase 1/2 Trial of GTX-102
03 Jan 2024 //
GLOBENEWSWIRE
Andelyn Selected by Ultragenyx for PPQ Manufacturing for Sanfilippo Syndrome
18 Dec 2023 //
PR NEWSWIRE
Ultragenyx Receives EC Decision for Evkeeza® (evinacumab) Expanded Indication
18 Dec 2023 //
GLOBENEWSWIRE
Bionano Genomics, Ultragenyx Pharmaceutical among healthcare movers
18 Oct 2023 //
SEEKING ALPHA
Ultragenyx Announces Program and Pipeline Updates at Analyst Day
16 Oct 2023 //
GLOBENEWSWIRE
Ultragenyx and Mereo Announce Interim Phase 2 Data Demonstrating Setrusumab
14 Oct 2023 //
GLOBENEWSWIRE
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023
09 Oct 2023 //
GLOBENEWSWIRE
Henrietta Lacks` estate sues Ultragenyx over gene therapy vector
11 Aug 2023 //
FIERCE PHARMA
Ultragenyx Announces First Patients Dosed in Ph3 Program Evaluating Setrusumab
06 Jul 2023 //
GLOBENEWSWIRE
Ultragenyx opens new gene therapy manufacturing site in Massachusetts
21 Jun 2023 //
ENDPTS
Ultragenyx & Mereo Announce Positive Data from Ph2/3 Orbit Study of Setrusumab
05 Jun 2023 //
GLOBENEWSWIRE
Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit
19 May 2023 //
GLOBENEWSWIRE
Ultragenyx Receives Agreement to Expand Global Ph 1/2 Trial Evaluating GTX-102
17 May 2023 //
GLOBENEWSWIRE
